Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–80
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Males or non-pregnant females age 18 to 65 years
Body Mass Index (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m\^2)
Diagnosis of at least mildly active adult-onset RA
Positive anti-citrullinated protein (ACPA) antibodies or rheumatoid factor
Regular use of MTX for at least 12 weeks and at a stable dose (10 to 25 mg/week) for at least 4 weeks prior to baseline
American College of Rheumatology (ACR) Functional Class I, II or III
You may not be if
Have received biologic agents within 3 months or 5 half-lives
Have surgery within 12 weeks prior to screening
Known history of human immunodeficiency virus (HIV infection and/or positive human HIV antibodies)
Have evidence of, or test positive for, hepatitis C virus or hepatitis B virus
Have evidence of active infection or fever
Have donated greater than 500 mL blood within 30 days prior to screening
Smoke greater than 10 cigarettes/day or equivalent
Have received live vaccine within 1 month of screening
Have a history of allergy to monoclonal antibodies or severe drug allergies
Have received prior or current treatment with biologic RA therapies
Have received a live vaccine 28 days prior to screening or intend to receive a live vaccine during the course of the study
Hemoglobin \< 10 grams per deciliter (g/dL), platelet count \< 100,000 cells/microliter (uL), total white blood cell count \< 3000 cells/uL, neutrophil count \< 2000 cells/uL, or lymphocyte count \< 500 cells/uL
Aspartate transaminase (AST) \> 1.5 x upper limit or the normal range (ULN), alanine transamine (ALT) \> 1.5 x ULN, creatinine \> 1.5 mg/dL (114 micromoles/liter \[uMol/L\])
Treatment with \> 10 mg/day or unstable dose of oral prednisone or equivalent within 28 days of baseline
Have required an increase in dose or a new prescription of narcotic within 28 days prior to randomization
Have received any parenteral corticosteroids within 28 days before screening
Treatment with any oral disease-modifying anti-rheumatic drugs (DMARDs) other than MTX within 4 weeks prior to baseline
Any neurological, psychiatric, vascular, or system disorder that could also affect the evaluation of disease activity assessments. Anemia of chronic disease is allowed if hemoglobin \> 10 g/dL
Have rheumatic or systemic autoimmune disease other than RA or significant active systemic involvement secondary to RA. Participants with secondary Sjogren's syndrome are eligible.
Uncontrolled arterial hypertension characterized by a confirmed systolic blood pressure of \> 150 mm Hg or diastolic blood pressure \> 90 mm Hg at screening or on day of study drug dosing
Poorly controlled diabetes as defined by glycosylated hemoglobin (HbA1c) \> 8.0% at screening
Known history of human immunodeficiency virus (HIV infection and/or positive human HIV antibodies)
Have evidence of, or test positive for, hepatitis C virus or hepatitis B virus
Clareo Health | A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)
